ASCO submitted comments to the Centers for Medicare & Medicaid Services on proposed changes to Medicare Advantage and Medicare Part D prescription plans for 2019. The comments included recommendations for updating prior authorization requirements as well as feedback on policies to address the national opioid epidemic.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO submitted comments to the Senate Finance Committee on addressing the opioid epidemic in the United States. ASCO is concerned about the epidemic and its devastating impact on too many Americans and wants to ensure that any efforts to address the epidemic do not inadvertently limit access to appropriate medical therapy for patients with cancer.
ASCO submitted comments to the U.S. Food and Drug Administration (FDA) to help guide its newly established Opioid Policy Steering Committee (OPSC). In the comments, ASCO responded to several FDA-posed questions to inform OPSC’s work of effectively addressing the nation-wide opioid crisis.